Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide

Satyanarayana Lakshminrusimha, Bobby Mathew, Corinne L. Leach

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Inhaled nitric oxide (iNO) is approved for use in persistent pulmonary hypertension of the newborn (PPHN) but does not lead to sustained improvement in oxygenation in one-third of patients with PPHN. Inhaled NO is less effective in the management of PPHN secondary to congenital diaphragmatic hernia (CDH), extreme prematurity, and bronchopulmonary dysplasia (BPD). Intravenous pulmonary vasodilators such as prostacyclin, alprostadil, sildenafil, and milrinone have been successfully used in PPHN resistant to iNO. Oral pulmonary vasodilators such as endothelin receptor antagonist bosentan and phosphodiesterase-5 inhibitors such as sildenafil and tadalafil are used both during acute and chronic phases of PPHN. In the absence of infection, glucocorticoids may also be effective in PPHN. Many of these pharmacologic agents are not approved for use in PPHN and our knowledge is based on case reports and small trials. Large multicenter randomized controlled trials with long-term follow-up are required to evaluate alternate pharmacologic strategies in PPHN.

Original languageEnglish (US)
Article number50885
Pages (from-to)160-173
Number of pages14
JournalSeminars in Perinatology
Volume40
Issue number3
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Persistent Fetal Circulation Syndrome
Pulmonary Hypertension
Nitric Oxide
Vasodilator Agents
Milrinone
Phosphodiesterase 5 Inhibitors
Bronchopulmonary Dysplasia
Lung
Alprostadil
Epoprostenol
Glucocorticoids
Randomized Controlled Trials

Keywords

  • Bosentan
  • Hypoxia
  • Iloprost
  • Milrinone
  • Nitric oxide
  • Oxygen
  • Prostacyclin
  • Sildenafil

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide. / Lakshminrusimha, Satyanarayana; Mathew, Bobby; Leach, Corinne L.

In: Seminars in Perinatology, Vol. 40, No. 3, 50885, 01.04.2016, p. 160-173.

Research output: Contribution to journalReview article

@article{80cd282b111a438c9a1326fdabfc426d,
title = "Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide",
abstract = "Inhaled nitric oxide (iNO) is approved for use in persistent pulmonary hypertension of the newborn (PPHN) but does not lead to sustained improvement in oxygenation in one-third of patients with PPHN. Inhaled NO is less effective in the management of PPHN secondary to congenital diaphragmatic hernia (CDH), extreme prematurity, and bronchopulmonary dysplasia (BPD). Intravenous pulmonary vasodilators such as prostacyclin, alprostadil, sildenafil, and milrinone have been successfully used in PPHN resistant to iNO. Oral pulmonary vasodilators such as endothelin receptor antagonist bosentan and phosphodiesterase-5 inhibitors such as sildenafil and tadalafil are used both during acute and chronic phases of PPHN. In the absence of infection, glucocorticoids may also be effective in PPHN. Many of these pharmacologic agents are not approved for use in PPHN and our knowledge is based on case reports and small trials. Large multicenter randomized controlled trials with long-term follow-up are required to evaluate alternate pharmacologic strategies in PPHN.",
keywords = "Bosentan, Hypoxia, Iloprost, Milrinone, Nitric oxide, Oxygen, Prostacyclin, Sildenafil",
author = "Satyanarayana Lakshminrusimha and Bobby Mathew and Leach, {Corinne L.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1053/j.semperi.2015.12.004",
language = "English (US)",
volume = "40",
pages = "160--173",
journal = "Seminars in Perinatology",
issn = "0146-0005",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide

AU - Lakshminrusimha, Satyanarayana

AU - Mathew, Bobby

AU - Leach, Corinne L.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Inhaled nitric oxide (iNO) is approved for use in persistent pulmonary hypertension of the newborn (PPHN) but does not lead to sustained improvement in oxygenation in one-third of patients with PPHN. Inhaled NO is less effective in the management of PPHN secondary to congenital diaphragmatic hernia (CDH), extreme prematurity, and bronchopulmonary dysplasia (BPD). Intravenous pulmonary vasodilators such as prostacyclin, alprostadil, sildenafil, and milrinone have been successfully used in PPHN resistant to iNO. Oral pulmonary vasodilators such as endothelin receptor antagonist bosentan and phosphodiesterase-5 inhibitors such as sildenafil and tadalafil are used both during acute and chronic phases of PPHN. In the absence of infection, glucocorticoids may also be effective in PPHN. Many of these pharmacologic agents are not approved for use in PPHN and our knowledge is based on case reports and small trials. Large multicenter randomized controlled trials with long-term follow-up are required to evaluate alternate pharmacologic strategies in PPHN.

AB - Inhaled nitric oxide (iNO) is approved for use in persistent pulmonary hypertension of the newborn (PPHN) but does not lead to sustained improvement in oxygenation in one-third of patients with PPHN. Inhaled NO is less effective in the management of PPHN secondary to congenital diaphragmatic hernia (CDH), extreme prematurity, and bronchopulmonary dysplasia (BPD). Intravenous pulmonary vasodilators such as prostacyclin, alprostadil, sildenafil, and milrinone have been successfully used in PPHN resistant to iNO. Oral pulmonary vasodilators such as endothelin receptor antagonist bosentan and phosphodiesterase-5 inhibitors such as sildenafil and tadalafil are used both during acute and chronic phases of PPHN. In the absence of infection, glucocorticoids may also be effective in PPHN. Many of these pharmacologic agents are not approved for use in PPHN and our knowledge is based on case reports and small trials. Large multicenter randomized controlled trials with long-term follow-up are required to evaluate alternate pharmacologic strategies in PPHN.

KW - Bosentan

KW - Hypoxia

KW - Iloprost

KW - Milrinone

KW - Nitric oxide

KW - Oxygen

KW - Prostacyclin

KW - Sildenafil

UR - http://www.scopus.com/inward/record.url?scp=84954285880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954285880&partnerID=8YFLogxK

U2 - 10.1053/j.semperi.2015.12.004

DO - 10.1053/j.semperi.2015.12.004

M3 - Review article

C2 - 26778236

AN - SCOPUS:84954285880

VL - 40

SP - 160

EP - 173

JO - Seminars in Perinatology

JF - Seminars in Perinatology

SN - 0146-0005

IS - 3

M1 - 50885

ER -